The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.
about
Emerging molecularly targeted therapies in castration refractory prostate cancerGastric cancer: The times they are a-changin'The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapyTargeting receptor tyrosine kinases in gastric cancerMolecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway BlockadeThe IGF Hormonal Network in Endometrial Cancer: Functions, Regulation, and Targeting ApproachesCombination therapy in combating cancer.Can we unlock the potential of IGF-1R inhibition in cancer therapy?Circulating tumour cells in the central and the peripheral venous compartment in patients with metastatic breast cancerAnticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab.Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation.Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.Targeting the insulin-like growth factor-1 receptor in human cancer.A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal.Insulin-like growth factor: current concepts and new developments in cancer therapy.Caloric restriction augments radiation efficacy in breast cancer.Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancerRole of the tumor microenvironment in the pathogenesis of gastric carcinoma.Type I insulin-like growth factor receptor signaling in hematological malignancies.Future directions in castrate-resistant prostate cancer therapy.Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies.The changing therapeutic landscape of castration-resistant prostate cancer.Targeting IGF-1 signaling pathways in gynecologic malignancies.Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapyManagement of advanced or recurrent cervical cancer: chemotherapy and beyond.Recent advances and future trends in the targeted therapy of metastatic gastric cancer.The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey.Biomarkers and novel agents in esophago-gastric cancer: are we making progress?Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions.ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents.IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination.Antibody therapeutics for treating prostate cancer: where are we now and what comes next?Risk of prostate cancer-specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence.Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study.Targeting IGF-1R: throwing out the baby with the bathwater?Pharmacokinetics and pharmacodynamics of figitumumab, a monoclonal antibody targeting the insulin-like growth factor 1 receptor, in healthy participants.Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.Molecular Signaling in Tumorigenesis of Gastric Cancer
P2860
Q21284745-3C6CC6B0-4442-45CB-AA32-ACBACDAA2D4BQ26776195-FF922F89-144E-489B-BDDE-6709B4F0BD11Q27000467-31A8AE4E-6331-4DA4-9B5C-6DBB397BD9B9Q27013050-3A47BD32-D156-4DD9-AB0F-BEB00B675DE7Q28088432-32E937FB-A762-4BBD-A742-BE11C826A336Q33658023-D82239F6-6AA9-4689-9DA4-A439C4BB067BQ33914234-7F28A761-D551-4DD4-BF0E-C4312740B3A9Q34336988-869899CE-34A9-4C8E-A70E-8F28BCCA43EDQ35006907-4544C598-8E51-46EA-825E-6B3C99422AF7Q35050195-999A14AD-F061-45EE-9BD3-F672239EB7A0Q35603263-75A00A21-0865-401D-995C-72A9DACA640AQ35863874-1F9A0E97-A1BA-4840-AC9A-DE999868A438Q36615766-AB270B36-5CBE-4B81-A675-3C7B7DDAEA44Q36708178-A893208F-8650-4172-B845-D1DD9CB04762Q37029389-D26F6CFA-DF8F-4A21-9DC9-AC7E283E9610Q37047067-C3C6F5E8-1AA9-45BA-846A-2807033DA63DQ37075928-DE78604F-273C-4527-986C-8325511B9536Q37127044-9EFC2C5B-529F-4752-8323-866A1131B964Q37596178-6039F346-8042-4B51-941E-1802CA007083Q37702186-4A26B2C4-A988-438A-8AFD-129C3F7E7A02Q37826274-4C9CC1E0-2460-4C69-BCEE-E8C013E80FB2Q37876194-61729804-7BC0-4863-80E9-B2B4DBEA4727Q37903335-4307E38F-5BEE-4ECF-8C46-264C720F715AQ37913983-914138E7-E440-419F-B337-7ED51E8AE204Q38072115-B085F93B-9A8D-4CA2-90C7-F6CACDE76B98Q38177688-77CD6BFE-7E63-4B75-8600-7619638B6B7FQ38178742-2307E31F-C96D-41A1-8982-1543F0E6924BQ38199128-F215D50B-9394-4D40-897E-20D2EDA2B97AQ38210070-7C3657DE-C717-47B9-8807-7566F3AA76ABQ38575013-39BAF157-3320-4D51-A88C-853F9B1C2AEBQ38653626-E90D3E08-62C5-4616-ADFF-3284A0F99593Q38883101-9C7217D5-29B2-43AB-9CCC-273A9FE5FA44Q38927010-DD6B5E53-009C-49E8-BBCA-964C2F1FB7F0Q39000185-1B9DD49E-02A0-45FE-950B-F62F6C43B316Q40954141-7D7909F1-79C9-4AB9-B8F1-02542857698AQ42367187-22DAD31F-DA9B-4B86-B867-D70F91E641F7Q42606238-4C791A96-B365-45D4-8031-6534901F3A62Q43623877-51252977-E92A-4DCE-96CD-FFAEBC8CD805Q46523280-19D99F94-21C9-4C36-829F-D2B1331174EAQ55429664-1E482DEF-0FF7-4F3D-830F-A36F582DEAB0
P2860
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The insulin-like growth factor ...... -escalation, open-label study.
@ast
The insulin-like growth factor ...... -escalation, open-label study.
@en
The insulin-like growth factor ...... -escalation, open-label study.
@nl
type
label
The insulin-like growth factor ...... -escalation, open-label study.
@ast
The insulin-like growth factor ...... -escalation, open-label study.
@en
The insulin-like growth factor ...... -escalation, open-label study.
@nl
prefLabel
The insulin-like growth factor ...... -escalation, open-label study.
@ast
The insulin-like growth factor ...... -escalation, open-label study.
@en
The insulin-like growth factor ...... -escalation, open-label study.
@nl
P2093
P2860
P356
P1476
The insulin-like growth factor ...... -escalation, open-label study.
@en
P2093
A Gualberto
A H M Reid
H-T Arkenau
J S de Bono
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605767
P407
P577
2010-07-13T00:00:00Z
P5875
P6179
1028559889